5 Slides We're Discussing: Overcoming Vaccine Hesitancy - Alaska
As the battle against COVID-19 continues across the globe, innovations in vaccine science and development have brought with them a whole slew of obstacles surrounding questions of vaccine efficacy, necessity, and their general trustworthiness. A new battle against misinformation has arisen. In this 5 Slides We're Discussing, we're joined by some of the leading experts in medical health and vaccine implementation from the state of Alaska to navigate this complex and highly interpersonal subject.
GLOBALink | Makeshift labs speed up COVID-19 testing in China's Heilongjiang
Makeshift nucleic acid testing labs have been put into use in Bayan County, the epidemic center for the new round of COVID-19 outbreak in China's Heilongjiang Province. The labs are capable of testing up to 30,000 samples a day. #GLOBALink
COVID-19 vaccine distribution effort
Key learnings from the ongoing vaccine distribution effort and paving the way for the future
GLOBALink | Vaccination the only good solution to solve COVID-19: Shanghai-based Italian doctor
Shanghai-based Italian doctor Giuseppe Bigatti has received Chinese #COVID19 vaccine shots, saying China's homegrown vaccines are safe and can effectively guard against the virus. #GLOBALink
Tourism Industry Conference 2021: Tourism in a Pandemic - Pivoting your Business
Tourism Industry Conference is organised annually by the Singapore Tourism Board as a collaborative platform for the tourism and travel trade industry to discuss strategies and opportunities for the industry moving forward.
In this year's conference, STB shared its recovery strategies and outlook on the future of tourism with an overarching theme - 'Weathering Disruptions, Emerging Stronger, and Preparing for our Future'. Featuring a first-ever hybrid event format with safety measures in place, our attendees experienced a seamless blend of in-person and virtual experiences with plenary sessions and virtual Q&As.
Your COVID-19 Questions Answered with PHL Health Experts – Part 2
On March 25, 2021, PHLCVB Chief Health Advisor and Dean Emeritus of Jefferson’s College of Population Health, Dr. David Nash, and Dr. Leonard Friedland, Vice President, Director Scientific Affairs and Public Health for GSK Vaccines and PHL Health Advisor, discussed COVID-19 testing, vaccine efficacy, and the state of events and gatherings.
#UnstoppablePHL
COVID-19 Town Hall: Dr. Joneigh S. Khaldun | Michigan's Plan to Administer the COVID-19 Vaccine
Dr. Joneigh S. Khaldun, chief medical executive and chief deputy director for health for the Michigan Department of Health and Human Services discusses the state’s plan to administer the COVID-19 vaccination and shares insight on the vaccine’s safety and efficacy.
Khaldun also engaged in a one-on-one discussion with Tammy Carnrike, chief operating officer of the Detroit Regional Chamber.
CareTalk Podcast Episode #49 - Vaccine Dreams: COVID Edition
In this episode of #CareTalk, David Williams (Health Business Group) and John Driscoll (CareCentrix) debate whether or not a coronavirus vaccine is coming around anytime soon.
(0:12) Are we close to a vaccine for the coronavirus pandemic?
(2:34) If/when a vaccine is available, will people actually get vaccinated?
(4:45) What should we expect a coronavirus vaccine to cost?
(7:21) How will the price Remdesivir be affected by the availability of a vaccine?
Subscribe to the #CareTalk Podcast:
iTunes:
Google Play:
Covid and Travel. What you need to know.
An Infection Prevention Specialist shares information and safety precautions regarding the pandemic. Learn what to be aware of when planning your next trip.
Learn more about the Evergreen Club by visiting our website:
.
.
#travelingover50 #seniortravel #evergreen #evergreenclub #evergreenclubhomestays #homestay #travel #community #adventure #safetravel
LJD Week 2020: Public Healthcare Procurement during the COVID-19 Pandemic
To respond more quickly to the Covid-19 global health crisis, governments around the world have been relaxing their existing national procurement laws. In this sessions, speakers will provide an overview of the expedited procurement processes that have been developed to address bottlenecks in the procurement of critical medical equipment, discuss the significant risks associated with looser restrictions and identify “best practices” that developing countries could follow for emergency procurement to mitigate the risk of corruption and ensure transparency.
COVID-19 Vaccination Update - Dr. Polsky - 03/23/21 - Calvert County, MD
The Board of County Commissioners (BOCC) received a COVID-19 update from Calvert County Health Officer Dr. Laurence Polsky during their March 23 meeting. Dr. Polsky, who directs the local health department as an agent of Maryland State Government, provided updates to the BOCC on vaccination efforts in Calvert County. Watch for the full presentation and discussion.
Critical Issues Series: COVID Forum
What: Covid Forum | What Employers Need to Know about Covid Vaccines, Testing, and the Path to Recovery
Why: The purpose of this forum is to provide timely, relevant information for the local business community as it relates to the Covid response and recovery effort.
About: The Covid Forum presented by 97.9 The Hill & Chapelboro.com, Duke Energy, and Durham Technical Community College is the first of ten forums in the 2021 Critical Issues Series. The Covid Forum will address what employers need to know right now as it relates vaccines, testing, and employment law - and - what employers need to know about the path ahead as it relates to long-term recovery and their business continuity planning.
When: Thursday, Feb 25, 2021 from 8:30-10am.
WHO plans to deliver two billion COVID 19 vaccine doses by end of 2021| CCTV English
The World Health Organization (WHO) has announced that it plans to deliver two billion doses of COVID-19 vaccine by the end of 2021. Some 500 million tests and 245 million courses of treatment will be provided to low and middle-income countries by mid-2021. Calling for global collaboration, the WHO urged that the development of vaccines be accelerated.
Evolving Travel Risk Management Solutions: Managing COVID-19 and ISO31030
Collinson, in partnership with Crisis24, a GardaWorld Company, are pleased to leverage over 55 years’ experience in medical and security assistance to bring you this webinar - designed to support businesses looking to evolve their current travel risk management solutions in light of COVID-19 and the upcoming ISO31030 Standard.
Coronavirus Vaccine latest news
Why is a coronavirus vaccine important?
The virus spreads easily and the majority of the world's population is still vulnerable to it. A vaccine would provide some protection by training people's immune systems to fight the virus so they should not become sick.
This would allow lockdowns to be lifted more safely, and social distancing to be relaxed.
What sort of progress is being made?
Research is happening at breakneck speed. About 80 groups around the world are researching vaccines and some are now entering clinical trials.
The first human trial data appears positive showing the first eight patients all produced antibodies that could neutralise the virus.
In Oxford, the first human trial in Europe has started with more than 800 recruits and have signed a deal with AstraZeneca to supply 100 million doses (30 million for the UK).
Pharmaceutical giants Sanofi and GSK have teamed up to develop a vaccine.
Australian scientists have begun injecting ferrets with two potential vaccines. It is the first comprehensive pre-clinical trial involving animals, and the researchers hope to test humans by the end of April
However, no-one knows how effective any of these vaccines will be.
When will we have a coronavirus vaccine?
A vaccine would normally take years, if not decades, to develop. Researchers hope to achieve the same amount of work in only a few months.
Most experts think a vaccine is likely to become available by mid-2021, about 12-18 months after the new virus, known officially as Sars-CoV-2, first emerged.
That would be a huge scientific feat and there are no guarantees it will work.
Four coronaviruses already circulate in human beings. They cause common cold symptoms and we don't have vaccines for any of them.
What still needs to be done?
Multiple research groups have designed potential vaccines, however, there is much more work to do.
Trials need to show the vaccine is safe. It would not be useful if it caused more problems than the disease.
Clinical trials will also need to show the vaccine provokes an immune response which would protect people from getting sick.
A way of producing the vaccine on a huge scale must be developed for the billions of potential doses.
Medicines regulators must approve it before it can be given.
Finally there will be the huge logistical challenge of actually inoculating most of the world's population.
Lockdowns could make this process slower. If fewer people are infected, it will take longer to know whether a vaccine actually works.
The idea of giving people the vaccine and then deliberately infecting them (known as a challenge study) would give quicker answers, but is seen as too dangerous while there is no known treatment.
How many people need to be vaccinated?
It is hard to know without knowing how effective the vaccine is going to be.
It is thought that 60-70% of people needed to be immune to the virus in order to stop it spreading easily (known as herd immunity).
But that would be billions of people around the world if the vaccine worked perfectly.
How do you create a vaccine?
Vaccines harmlessly show viruses or bacteria (or even small parts of them) to the immune system. The body's defences recognise them as an invader and learn how to fight them.
Then if the body is ever exposed for real, it already knows what to do.
The main method of vaccination for decades has been to use the original virus.
The measles, mumps and rubella (MMR) vaccine is made by using weakened viruses that cannot cause a full-blown infection. The seasonal flu jab takes the main strains of flu doing the rounds and completely disables them.
The work on a new coronavirus vaccine is using newer, and less tested, approaches called plug and play vaccines. Because we know the genetic code of the new coronavirus, Sars-CoV-2, we have the complete blueprint for building it.
Researchers in Oxford have put small sections of its genetic code into a harmless virus that infects chimpanzees. They hope they have developed a safe virus that looks enough like the coronavirus to produce an immune response.
Other groups are using pieces of raw genetic code (either DNA or RNA depending on the approach) which, once injected into the body, should start producing bits of viral proteins which the immune system again can learn to fight.
Would a vaccine protect people of all ages?
It will, almost inevitably, be less successful in older people, because aged immune systems do not respond as well to immunisation. We see this with the annual flu jab.
It may be possible to overcome this by either giving multiple doses or giving it alongside a chemical (called an adjuvant) that gives the immune system a boost.
Who would get a vaccine?
If a vaccine is developed, then there will be a limited supply, at least initially, so it will be important to prioritise.
Healthcare workers who come into contact with Covid-19 patients would top the list. The disease is most deadly in older people so they would be affected the most.
Managing non-financial risk during a crisis: applying lessons learned from covid-19
How have non-financial risks evolved as a result of the pandemic?
In many cases risk exposure increased almost overnight as the implementation of digital technologies had to be accelerated.
Are the traditional tools and frameworks that are used to manage those risks fit for purpose in a rapidly changing environment?
Andrea Pozzi, Head of Non-Financial Risk Management, Santander explores these issues in this webinar.
--------
Andrea Pozzi joined Grupo Santander as the Global Head of Non-Financial Risk in June of 2018 and is based in Madrid, Spain. Prior to joining Santander she was principal of Percival Advisory LLC, a risk management consulting and advisory practice that she founded in 2017.
Andrea has over twenty years of Risk Management experience. Prior to forming her advisory practice, Andrea was the Head of Operational Risk Management at Citadel LLC. Before joining Citadel she was a Managing Director and the Global Head of Operational Risk Management for Citigroup. Andrea had been with Citi for more than eleven years. As the Global Head of Op Risk Management she: managed a global team of op risk professionals covering 102 countries; determined and drove the strategic direction of Operational Risk Management; created lasting solutions for minimizing operational risk losses; challenged the business on both historical and proposed practices; and worked as an independent partner to drive solutions to mitigate risk. In addition, she put in place robust and consistent global standards, framework and structure for Operational Risk Management; developed and created innovative techniques for assessing and quantifying Operational Risk; and led two global, cross-functional (with Finance, O&T, and the business) programs to predict and detect internal fraud.
During her time at Citi she spent five years in Mexico City as the Mexico and Latin American Head of Operational Risk Management. In that role she established the Op Risk function for the Latin America (“LatAm”) and Mexico region and managed a regional team of risk professionals covering 24 countries, including Mexico (Banamex)
Prior to Citi, Andrea worked in several Market Risk and Credit Risk Management roles at Munich Re Capital Management, Merrill Lynch and PricewaterhouseCoopers, where she was a consultant in the Financial Risk Management practice and a significant contributor to Operational Risk the Next Frontier; Benchmarking - A Tool for Continuous Improvement. Andrea began her career as an analyst in the Financial Research department of the Chicago Mercantile Exchange where she helped to develop and launch new derivatives (futures and options).
Andrea is fluent in Spanish and Italian. She holds a B.A. from McGill University and an M.B.A. from the University of Chicago.
Professor Luke O’Neill on vaccines, variants and reopening the travel, tourism & hospitality economy
This week the Irish Tourism Industry Confederation (ITIC) spoke with Professor of Biochemistry and Immunology Luke O’Neill on how society and the economy is winning the battle against Covid. Positive, engaging and stimulating, Luke discusses how international travel can restart, how we must live alongside variants, the importance of embracing antigen testing, and how the Irish Government and public health authorities have been too conservative and cautious in balancing the pandemic with the country’s economic needs.
Luke O'Neill There is a 19 fold decrease in risk from Covid just by going outdoors
There is a 19 fold decrease in risk from Covid just by going outdoors, Luke O'Neill speaking at Irish Tourism Industry Confederation conference, February 10 2021
Vaccination Availability post-COVID - Horasis Extraordinary Meeting, October 1, 2020
Vaccination Availability post-COVID
COVID-19 vaccines will take a long time to pass regulatory hurdles, even with agile parallel development: some people may risk lightly regulated early release COVID vaccines. Is global co-operation going to take place? When will a COVID vaccine finally be ready?
• José Ramón Calvo, President, Institute of Multidisciplinary Research, Spain
• Ken Hu, President and Chief Executive Officer, Kindwell Inc., USA
• Brett Johnson, Co-founder and Chief Executive Officer, Altru Institute, USA
• Grace Lee, Professor of Pediatrics, Stanford University School of Medicine, USA
• Yang Min, Entrepreneur in Residence, Northern Light Venture Capital, China
• Faheem Younus, Professor, University of Maryland Upper Chesapeake Hospital, USA
Chaired by
• Lloyd B. Minor, Dean, Stanford University School of Medicine, USA
How Technology Helps the World Keep Working During COVID19 - Horasis USA Meeting 2022
From the science behind innovative therapies, through maintaining health and education, technology enabled governments kept delivering for citizens during the pandemic. Is an expedited digital transformation here to stay? What challenges remain to be conquered so progress can be expanded upon? How can the momentum for modernization be turned into meaningful and just public value creation for everyone?
• Mohit Joshi, President, Infosys, United Kingdom
• Betty Enyonam Kumahor, Founder and Managing Partner, The Cobalt Partners, Ghana
• Kouhei Kurihara, Co-Founder, Privacy By Design Lab, Japan
• Srikar Reddy, Chief Executive Officer, Sonata Software, India
• Gary J. Shapiro, President and Chief Executive Officer, Consumer Technology Association, USA
Chaired by
• Jerry Power, Founder, I3 Systems, USA